(E)-N-((S)-3-(3,5-difluorophenyl)-1-(((6S,8aS,14aS,20S,23aS)-6-methyl-5,8,14,19,23-pentaoxooctadecahydro-1H,5H,14H,19H-pyrido[2,1-i]dipyrrolo[2,1-c:2',1'-l][1]oxa[4,7,10,13]tetraazacyclohexadecin-20-yl)amino)-1-oxopropan-2-yl)hept-2-enamide | 1542206-53-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (E)-N-((S)-3-(3,5-difluorophenyl)-1-(((6S,8aS,14aS,20S,23aS)-6-methyl-5,8,14,19,23-pentaoxooctadecahydro-1H,5H,14H,19H-pyrido[2,1-i]dipyrrolo[2,1-c:2',1'-l][1]oxa[4,7,10,13]tetraazacyclohexadecin-20-yl)amino)-1-oxopropan-2-yl)hept-2-enamide
• 英文别名: (E)-N-[(2S)-3-(3,5-difluorophenyl)-1-[[(3S,9S,13S,19S,22S)-19-methyl-2,8,12,18,21-pentaoxo-11-oxa-1,7,17,20-tetrazatetracyclo[20.4.0.03,7.013,17]hexacosan-9-yl]amino]-1-oxopropan-2-yl]hept-2-enamide
• CAS: 1542206-53-0
• 化学式: C₃₈H₅₀F₂N₆O₈
• 分子量: 756.847
• InChiKey: FCMOOMATFYSOML-PGRVSJJVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  54
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  175
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 碳酸氢钠 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.5h， 生成 (E)-N-((S)-3-(3,5-difluorophenyl)-1-(((6S,8aS,14aS,20S,23aS)-6-methyl-5,8,14,19,23-pentaoxooctadecahydro-1H,5H,14H,19H-pyrido[2,1-i]dipyrrolo[2,1-c:2',1'-l][1]oxa[4,7,10,13]tetraazacyclohexadecin-20-yl)amino)-1-oxopropan-2-yl)hept-2-enamide
  参考文献：
  名称：

  Restriction of the Conformational Dynamics of the Cyclic Acyldepsipeptide Antibiotics Improves Their Antibacterial Activity

  摘要：

  The cyclic acyldepsipeptide (ADEP) antibiotics are a new class of antibacterial agents that kill bacteria via a mechanism that is distinct from all clinically used drugs. These molecules bind and dysregulate the activity of the ClpP peptidase. The potential of these antibiotics as antibacterial drugs has been enhanced by the elimination of pharmacological liabilities through medicinal chemistry efforts. Here, we demonstrate that the ADEP conformation observed in the ADEP-ClpP crystal structure is fortified by transannular hydrogen bonding and can be further stabilized by judicious replacement of constituent amino acids within the peptidolactone core structure with more conformationally constrained counterparts. Evidence supporting constraint of the molecule into the bioactive conformer was obtained by measurements of deuterium-exchange kinetics of hydrogens that were proposed to be engaged in transannular hydrogen bonds. We show that the rigidified ADEP analogs bind and activate ClpP at lower concentrations in vitro. Remarkably, these compounds have up to 1200-fold enhanced antibacterial activity when compared to those with the peptidolactone core structure common to two ADEP natural products. This study compellingly demonstrates how rational modulation of conformational dynamics may be used to improve the bioactivities of natural products.

  DOI：

  10.1021/ja410385c

文献信息

• [EN] ENOPEPTIN ANALOGAS AND METHODS OF USE THEREOF<br/>[FR] ANALOGUES D'ENOPEPTINE S ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV BROWN

  公开号：WO2016037072A2

  公开（公告）日：2016-03-10

  Described herein are enopeptin analogs of Formula (I) or (II): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R1, R2, R3, R4, R5, R6, m, X, RXa, and Y are as defined herein. Such compounds have been found to exhibit antibacterial activity, to competatively interfere with the bacterial efflux pump, and/or to potentiate the activities of other anti-bacterial agents, such as an ADEP4, against bacteria that are not susceptible due to efflux pumps. Further provided are a methods of such compounds treatment and use.